Skip to main content
Home > BioCentury on BioBusiness > Finance/Investment

Chronological Index of : Finance

 Current Issue
  • Summer sweeteners

    How biotechs tapping the market are sweetening their deal terms

    Ebb & Flow Ebb & Flow Summer sweeteners Figure: Money Raised in 2016 Biotechs looking to tap the markets are sweetening their deal terms with deep discounts or bells and whistles such as warrants. The goal is …

    Published on 5/23/2016
  • Herding an atypical syndicate

    How Caribou aligned its series B syndicate with its CRISPR business areas

    Ebb & Flow Herding an atypical syndicate Unlike its gene editing peers that are going deep into therapeutics, Caribou Biosciences Inc. has been going wide, exploring numerous sectors where its CRISPR-Cas9 …

    Published on 5/23/2016
  • Venturing west

    How newly formed Taiho Ventures plans to spend its $50 million fund

    Ebb & Flow Venturing west After two years as an LP, Taiho Pharmaceutical Co. Ltd. is taking the plunge and creating its own strategic venture unit. The company isn't providing many details about its $50 million …

    Published on 5/23/2016
  • Figure: Money Raised in 2016

    Summer sweeteners Money Raised in 2016 Last week, the biotech industry raised $346 million, bringing to $12.9 billion the total raised year-to-date. In 2015, a total of $108.9 billion was raised, including $54.8 …

    Published on 5/23/2016
  • Home sweet krone

    Why Swedish rare disease play Wilson Therapeutics stayed local with its IPO

    Ebb & Flow Home sweet krone Wilson Therapeutics AB (SSE:WTX) opted to list locally in Stockholm and secured enough cash to ignore the markets until 2020, which is when it plans to hire a sales force for its rare …

    Published on 5/23/2016
  • Figure: Capital rationing

    Global ambitions Capital rationing Last year, the average raised per private European company increased by 47% to $22.2 million from $15.1 million in 2014, helped by a few companies that secured significant funds.…

    Published on 5/16/2016
  • Figure: Clinical rationing

    Global ambitions Clinical rationing The total raised by private and public European biotechs with lead programs in clinical development rose by 42% to $4.7 billion in 2015 from $3.3 billion in 2014. The increase …

    Published on 5/16/2016
  • Figure: Competition for capital

    Global ambitions Competition for capital Total funding continued to increase in the U.S. and the EU, but European-domiciled companies continued to receive a modest share of the total. Last year, the money raised …

    Published on 5/16/2016
  • Figure: Hallmarks of ambition

    Global ambitions Hallmarks of ambition The 15 U.S. VCs who invested in the greatest number of rounds worldwide during 2010-15 put their money to work in Europe in innovative companies with ambitious pipelines, …

    Published on 5/16/2016
  • Figure: Missed opportunity

    Global ambitions Missed opportunity Between the start of 2013 and mid-2015, U.S. biotech share prices grew at nearly twice the rate of their European counterparts. But even as U.S. investors began to complain that…

    Published on 5/16/2016
  • Figure: Private financings

    Global ambitions Private financings The average money raised by private European biotechs increased by 47% to $22.2 million in 2015 vs. $15.1 million in 2014; however, the amount still lags the $32 million average…

    Published on 5/16/2016
  • Figure: Public financings

    Global ambitions Public financings The top figure shows that the amount raised via equity financings by public European biotechs rose 1.7x to $8.1 billion in 2015 vs. a 1.4x increase in the U.S. to $24.3 billion. …

    Published on 5/16/2016
  • Figure: U.S. investors close the gap

    Global ambitions U.S. investors close the gap European-domiciled public companies that attracted U.S. investors through a U.S. listing raised nearly as much on average as public companies domiciled in the U.S. The…

    Published on 5/16/2016
  • Figure: U.S. VCs stepping up

    Global ambitions U.S. VCs stepping up The 15 U.S. VCs who invested in the greatest number of rounds worldwide during 2010-15 drove up the average round size compared with all European rounds. The average round for…

    Published on 5/16/2016
  • Table: New funds

    Global ambitions New funds Since the start of 2015, at least 31 life science funds with a European presence are raising or have raised a total of more than $8 billion. Funds are listed in descending order by size.…

    Published on 5/16/2016
  • Table: U.S. investment in top rounds

    Global ambitions U.S. investment in top rounds U.S. investors participated in at least seven of 10 European venture equity financings of $80 million or more since the start of 2015. Firms with headquarters in the U.…

    Published on 5/16/2016
  • Global ambitions

    Why European biotechs should start courting U.S. capital now

    European biotechs with the drive to compete on a global scale should start courting U.S. investors now, before the U.S. markets heat back up.

    Published on 5/16/2016
  • Scarcity value

    Why Intellia's venture investors couldn't get enough of the IPO

    Ebb & Flow Ebb & Flow Scarcity value Scarcity value trumped dour market conditions a second time as Intellia Therapeutics Inc. (NASDAQ:NTLA) debuted with the highest-ever postmoney valuation for a preclinical …

    Published on 5/16/2016
  • Naurex's New Leaf

    Why New Leaf led a $65M A round for Naurex spinout Aptinyx

    Ebb & Flow Naurex's New Leaf With a clinically validated MOA and a broadly applicable discovery platform, the former Naurex Inc. team convinced new investor New Leaf Venture Partners to lead a tranched $65 million …

    Published on 5/16/2016
  • Figure: Money Raised in 2016

    A clot to consider Money Raised in 2016 Last week, the biotech industry raised $622 million, bringing to $11.9 billion the total raised year-to-date. In 2015, a total of $108.9 billion was raised, including $54.8 …

    Published on 5/9/2016
  • Table: Earnings on deck

    A clot to consider Earnings on deck At least 18 biotechs and pharmas are expected to report earnings this week. (A) EPS for fiscal year ended March 31, 2015; (B) Fiscal 4Q Company Date Pre/post mkt 1Q16 EPS …

    Published on 5/9/2016
  • Elements of infrastructure

    Detailing iCarbonX's to-do list after the Chinese biotech's big series A

    Ebb & Flow Elements of infrastructure With big data infrastructure creation at the top of iCarbonX's to-do list, the Shenzhen-based personalized health management company tapped Chinese internet giant Tencent …

    Published on 5/9/2016
  • Table: venBio's portfolio

    ven and now venBio's portfolio venBio LLC has had three exits via pharma takeouts from its first fund — Aragon Pharmaceuticals Inc., Seragon Pharmaceuticals Inc. and Labrys Biologics Inc. — and continues to expect…

    Published on 5/9/2016
  • A clot to consider

    Weighing the pros and cons of Biogen's planned hemophilia spinout

    The factors underlying Biogen's hemophilia spinout. Plus: BB Biotech's trans-Atlantic transactions; and iCarbonX (inter)nets a series A.

    Published on 5/9/2016
  • Buying the battered

    Why BB Biotech is shifting money to downtrodden U.S. biotechs

    Ebb & Flow Buying the battered BB Biotech AG (SIX:BION; Xetra:BBZA) is starting to take advantage of a gap between U.S. and European biotech stock declines it believes has grown too wide. The firm is looking to …

    Published on 5/9/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993